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Abstract
Background: Accumulating evidence indicates that RNA oxidation is involved in a wide variety of neurological diseases and
may be associated with neuronal deterioration during the process of neurodegeneration. However, previous studies were
done in postmortem tissues or cultured neurons. Here, we used transgenic mice to demonstrate the role of RNA oxidation
in the process of neurodegeneration.
Methodology/Principal Findings: We demonstrated that messenger RNA (mRNA) oxidation is a common feature in
amyotrophic lateral sclerosis (ALS) patients as well as in many different transgenic mice expressing familial ALS-linked
mutant copper-zinc superoxide dismutase (SOD1). In mutant SOD1 mice, increased mRNA oxidation primarily occurs in the
motor neurons and oligodendrocytes of the spinal cord at an early, pre-symptomatic stage. Identification of oxidized mRNA
species revealed that some species are more vulnerable to oxidative damage, and importantly, many oxidized mRNA
species have been implicated in the pathogenesis of ALS. Oxidative modification of mRNA causes reduced protein
expression. Reduced mRNA oxidation by vitamin E restores protein expression and partially protects motor neurons.
Conclusion/Significance: These findings suggest that mRNA oxidation is an early event associated with motor neuron
deterioration in ALS, and may be also a common early event preceding neuron degeneration in other neurological diseases.
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Introduction
Oxidative damage is believed to be an important contributor to
the pathogenesis of many neurodegenerative diseases including
amyotrophic lateral sclerosis (ALS) [1]. It results from modification
of vital cellular components, including proteins, lipids and nucleic
acids, by free radicals. Reactive oxygen species can hydroxylate
guanine to produce 8-oxo-7,8-dihydroguanosine (8-OHG) in
RNA, the most abundant oxidized base [2,3]. Nunomura et al.
[4] showed that most of the oxidized nucleosides are associated
with cytoplasmic RNA and are restricted to vulnerable neurons in
the brains of Alzheimer’s disease (AD). Similar RNA oxidation in
neuronal cytoplasm was also observed in other disorders [5–10].
We previously demonstrated that up to 50% of messenger RNA
(mRNA) are oxidized in AD frontal cortices [11]. Some mRNA
species are more susceptible to oxidative damage, and many of
them have been implicated in the pathogenesis of AD [12].
Oxidized mRNA cannot be translated properly leading to reduced
protein expression and consequently, loss of normal protein
function [12–14]. Ribosomal RNA oxidation was also reported in
AD brains [15,16]. There is a considerable amount of evidence
supporting an early involvement of RNA oxidation in the
pathological cascade of neurodegeneration [4,13,15,17,18].
ALS is a fatal neurodegenerative disorder that is characterized by
progressive degeneration ofmotorneuronsinthe spinal cord,motor
cortex and brainstem [19]. The majority of cases have no genetic
component, i.e. sporadic ALS (SALS). Approximately 5% of ALS
cases are familial (FALS), usually with an autosomal dominant
inheritance pattern. About 15–25% of FALS cases are linked to
mutation in the gene encoding the antioxidant enzyme Cu
2+/Zn
2+
superoxide dismutase (SOD1). It is believed that multiple
mechanisms underlie the disease progression [19]. Oxidative stress
is considered to be one of the important factors [1].
Over-expression of some of FALS-linked mutant SOD1
proteins in transgenic mice results in the development of a
neurological disorder that resembles ALS [20]. Mutant SOD1
causes motor neuron degeneration by acquiring a toxic gain of
function property rather than by the loss of enzymatic activity
[21]. Many studies have shown that the mutant SOD1 toxicity to
motor neurons is non-cell autonomous, i.e. mutant damage is
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In the present study, we investigated whether RNA oxidation plays
a role in the pathogenesis of motor neuron degeneration. Our data
indicate that RNA oxidation is a common feature in ALS and that
RNA oxidation may occur early in disease pathogenesis and
promote motor neuron deterioration in ALS.
Results
Poly(A)
+ mRNAs isolated from ALS-affected areas are
oxidized
We previously developed an immunoprecipitation (IP) proce-
dure using the monoclonal antibody 15A3, which recognizes 8-
OHG in the oxidized RNA, to isolate oxidized RNA [12]. We
used this established procedure to investigate whether mRNAs are
oxidized in ALS postmortem tissues. The following postmortem
tissues were examined: 11 SALS motor cortices, 10 SALS lumbar
spinal cords, 2 FALS motor cortices (without SOD1 mutations), 5
SALS cerebellums, 5 age-matched normal motor cortices, and 1
age-matched normal lumbar spinal cord. Poly(A)
+ mRNAs were
isolated from each tissue, and oxidized mRNAs were separated
from non-oxidized mRNAs by IP with 15A3 antibodies. The
isolated oxidized mRNAs were then reverse transcribed to cDNAs
with DIG-labeled dUTPs to facilitate analysis by Southern
blotting. Among 11 SALS motor cortex samples, 3 samples
showed strong signals on the Southern blot such as SALS1
(Fig. 1A, lane 3), 5 samples showed moderate signals such as
SALS2 (lane 4), and 3 samples showed weak signals such as SALS3
(lane 5). Both FALS motor cortex samples showed moderate
signals (lane 6 and 7). Among 10 SALS spinal cord samples, 6
samples showed moderate signals such as SALS2 (lane 8), and 4
samples showed very weak signals such as SALS1 (lane 9). There
was no or very weak signals in ALS cerebellum (lane 10), normal
motor cortex (lane 11) or normal spinal cord (lane 12). A no-
antibody control (lane 1) and an 8-OHG-blocked antibody control
(lane 2) were also carried out to confirm that the precipitated
mRNAs were oxidized mRNAs. The increased mRNA oxidation
in ALS tissues did not result from agonal state of disease because it
was not observed in the unaffected areas, cerebellum. Further, the
postmortem interval did not affect the amount of immunoprecip-
itated mRNAs. These results indicated that mRNAs are
oxidatively damaged to a variable extent in ALS patients.
We quantified the magnitude of mRNA oxidation by compar-
ing the signal densities of oxidized mRNAs (immunoprecipitated
RNAs) to serial dilutions of non-oxidized mRNA (unprecipitated
RNAs) via Southern blot analysis. Quantitative analysis revealed
that about 6–10% of the mRNAs were oxidized in ALS tissues
showing strong signals on the Figure 1A Southern blot such as the
SALS1 motor cortex (Fig. 1B), and about 3–5% of the mRNAs
were oxidized in ALS tissues showing moderate signals.
Significant amounts of poly(A)
+ mRNAs are oxidized in
the spinal cords of mutant SOD1 mice at the pre-
symptomatic stage
We investigated whether mRNA oxidation occurs in transgenic
mice expressing FALS-linked mutant SOD1. We first examined
mRNA prepared from the spinal cords of 60 day-old (pre-
symptomatic stage) SOD1
G93A mice. Non-transgenic littermates
and age-match transgenic mice over-expressing wild-type SOD1
(SOD1
WT) were used as controls (n=3 per group). Oxidized
mRNAs (O) were separated from non-oxidized mRNAs (N)b yI P
with 15A3 antibodies and then analyzed by Southern blotting.
Approximately 30% and 4% of total spinal cord mRNAs were
oxidized in SOD1
G93A (Fig. 1C, G93A) and SOD1
WT (Fig. 1C,
WtSOD1) spinal cords, respectively, while a trace amount of
mRNA was oxidized in non-transgenic spinal cords (Fig. 1C, WT).
These results indicated a significant oxidative damage of mRNAs
in the spinal cords of SOD1
G93A mice at an early, pre-
symptomatic stage. We further examined oxidized mRNA level
in the end stage of SOD1
G93A spinal cords. The results showed
that much lower amounts of total spinal cord mRNAs were
oxidized (,10% or less) in the end stage compared to the pre-
symptomatic stage (Fig. 1D), which was consistent with the above
ALS postmortem tissues study (Fig. 1A).
Furthermore, we examined whether mRNA oxidation occurs in
other mutant SOD1 transgenic mice at pre-symptomatic stage,
including SOD1
G37R (2 month-old), SOD1
G85R (4 month-old),
SOD1
G127X (5.5 month-old), and SOD1
His46R/His48Q (6 month-old)
(n=3 per group). These mice develop the disease onsets at age of
,7–15.5 months. Southern blot analysis of 15A3-immunoprecip-
itated mRNAs prepared from the spinal cords showed similar levels
of oxidized mRNA in SOD1
G127X and SOD1
His46R/His48Q but less
in SOD1
G37R and SOD1
G85R compared to SOD1
G93A (Fig. 1E).
These results suggest that mRNAoxidationmaybe a commonearly
event preceding motor neuron degeneration in ALS.
A significant increase in RNA oxidation in the motor
neurons and oligodendrocytes of the SOD1
G93A spinal
cord at pre-symptomatic stage
To better understand at which stage RNA oxidation occurs and
whether RNA oxidation plays a role in the pathogenesis of motor
neuron degeneration, we further investigated RNA oxidation in
SOD1
G93A mice. We first examined what cell types showed
increased RNA oxidation in the lumbar spinal cord from different
ages of SOD1
G93A mice or non-transgenic littermates (n=3 per
group). Immunofluorescent staining was performed using the
15A3 antibody, which recognizes both 8-OHG and 8-OHdG,
markers of oxidative damage to RNA and DNA respectively. The
intensity of 15A3 immunofluorescence was significantly increased
in 45 day-old SOD1
G93A mice (Fig. 2D) and further enhanced in
60 day-old SOD1
G93A mice (Fig. 2B&E), while only a very faint
signal was detected in non-transgenic littermates (Fig. 2A&C).
15A3 immunoreactivity was prominent in the ventral horn motor
neurons as judged by their characteristic size and morphology. In
addition, a significant increase of 15A3 immunoreactivity was also
observed in the white matter oligodendrocytes (Fig. 2K&L) as
identified by CC1 immunostaining (Fig. 2M). Importantly, 15A3
signal intensity was prominent in the cytoplasm and was
diminished greatly by the RNase treatment (Fig. 2J) but only
slightly by DNase I treatment, which indicated that cytoplasmic
RNA was the major site of nucleic acid oxidative damage.
Moreover, the immunoreactivity was diminished completely when
the antibody was pre-incubated with 8-OHG (Fig. 2I), indicating
that the observed fluorescent signal was specific to oxidized base 8-
OHG in RNA. During the symptomatic stage, 15A3 signal
intensity was decreased in 90 day-old SOD1
G93A mice (Fig. 2F),
and further reduced in 110 day-old SOD1
G93A mice (Fig. 2G).
The 15A3 immunoreactivity was low in the dying motor neurons,
and started to appear in the glial cells, which was significant at the
end stage (Fig. 2H). Figure 2P shows the statistical analysis of
motor neuron 15A3 immunofluorescence intensity. We also
examined brain sections from 60 day and 90 day-old SOD1
G93A
mice as well as non-transgenic littermates. No increase in 15A3
immunofluorescence was observed (Fig. 2N&O). These results
indicated that RNA oxidation occurs as early as 45 days of age,
progressively increasing with age until it peaks at 60–70 days of
age (when the motor neurons still look healthy) and then
diminishes when the motor neurons begin to degenerate.
mRNA Oxidation in ALS
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To further examine those motor neurons showing strong 15A3
immunoreactivity, we performed nuclear staining using chroma-
tin-binding dye bis-benzimide (Hoechst 33342). The results
showed that motor neurons with strong 15A3 signal had normal
nuclear and chromatin morphology (Fig. 3A, G93A 60d). At the
symptomatic stage (90 days), the dying motor neurons showed
abnormal nuclear and chromatin morphology but less 15A3
immunoreactivity (Fig. 3A, G93A 90d). Mitochondrial vacuoliza-
tion is considered to be one of the earliest molecular pathological
changes in SOD1
G93A mice. We examined mitochondrial
Figure 1. mRNAs are oxidatively damaged in ALS-affected areas and pre-symptomatic stage of mutant SOD1 mice. (A) Southern blot
analysis of 15A3-immunoprecipitated oxidized mRNAs in ALS patients. mctx, motor cortex; sc, spinal cord; cbm, cerebellum; no Ab, no antibody; Ab
block, antibody block (antibodies pre-incubated with 8-OHG). (B) Quantitative analysis of the magnitude of mRNA oxidation by comparing the signal
density of oxidized mRNAs (Oxi) to serial dilutions of non-oxidized mRNA (Non-oxi) via Southern blot analysis. An example of analysis of SALS1 motor
cortex is shown. The non-oxidized mRNA fraction was diluted 1 to 15. (C) Southern blot analysis of oxidized (O) and non-oxidized (N) mRNA pools
prepared from spinal cords of indicated mice (60 day-old, n=3). The percentages of total spinal cord mRNA that were oxidized in SOD1
G93A (G93A),
SOD1
WT (WtSOD1), and non-transgenic (WT) mice are about 30%, 3–5%, and barely detectable, respectively. No mRNA was precipitated in the
SOD1
G93A sample when 15A3 antibodies were pre-incubated with 8-OHG (Ab block). (D) Less amount of spinal cord mRNAs were oxidized (,10% or
less) in the end stage of SOD1
G93A mice (n=3?). (E) RNA oxidation occurred in the pre-symptomatic stage of different mutant SOD1 mice. Oxidized
mRNA pools were prepared from the spinal cords of indicated mutant SOD1 mice (n=3). The ages of tested mice (Age) and the age of onset (Onset)
are noted. Right panel shows densitometry analysis of Southern blot results.
doi:10.1371/journal.pone.0002849.g001
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motor neurons with strong 15A3 immunoreactivity had only minor
mitochondrial vacuolization (Fig. 3B). Ubiquitinated protein aggre-
gation is a hallmark of degenerating motor neurons. We did not
observe ubiquitinated protein aggregation in motor neurons with
strong 15A3 immunoreactivity at age of 60 days (Fig. 3C). These
results indicate that thosemotor neurons showing RNA oxidation still
appear to be healthy, and that RNA oxidation is an early event.
Figure 2. Increased RNA oxidation in motor neurons and oligodendrocytes of SOD1
G93A spinal cord at pre-symptomatic stage.
Lumbar spinal cord sections from different ages of SOD1
G93A mice (G93A) and non-transgenic littermates (WT) were immunolabeled with 15A3
antibodies. The intensity of 15A3 immunofluorescence in SOD1
G93A mice was significantly increased at 45 days of age (D), further enhanced at 60
days of age (B, E), and then diminishes during the symptomatic stage (F, G, H), while only a very faint signal was detected in non-transgenic
littermates (A, C). 15A3 immunoreactivity was prominent in the ventral horn motor neurons and the white matter oligodendrocytes (K, L), as
identified by CC1 immunostaining (M). No increase of 15A3 immunofluorescence was observed in the brain sections (N, O). The immunoreactivity
was diminished greatly by the RNase treatment (J) and when the antibody was pre-incubated with 8-OHG (I). Scale bar, 50 mm. (P) Statistical analysis
of motor neuron 15A3 immunofluorescence intensity (n=20). Asterisks indicate statistical significance compared with WT, 60 d (*P,0.0001).
doi:10.1371/journal.pone.0002849.g002
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To identify oxidized mRNA species, we performed DNA
microarrays using Affymetrix GeneChip Mouse Genome 430 2.0.
This array can analyze ,39,000 transcripts. Three arrays were
performed, and in each array, oxidized mRNAs were prepared
from two spinal cords of 60-day old SOD1
G93A mice so a total of
six mice were analyzed. A total of 3,409 mRNA species were
identified, and these oxidized mRNA species and their relative
signal intensities on the chips were similar among the three arrays.
Semi-quantitative PCR analysis was then performed to verify that
the identified mRNA species were present in the oxidized mRNA
pool. As shown in Figure 4A, ribosome protein S6, cytochrome c
oxidase Va, cytochrome c and myelin basic protein (MBP)
mRNAs, which had strong signal intensities on the arrays, were
present in the oxidized mRNA pool. Microtubule-associated
protein 2 (MAP2) and pericentriolar material 1 (PCM1) mRNAs,
which had very weak signal intensities on the arrays, were hardly
Figure 3. RNA oxidation is an early event preceding motor neuron degeneration. Lumbar spinal cords from indicated age of SOD1
G93A
mice (G93A) and non-transgenic littermates (WT) were examined. (A) In the ventral horn, motor neurons with strong 15A3 immunoreactivity had
normal nuclear and chromatin morphology by Hoechst 33342 staining; the dying motor neurons showed abnormal nuclear and chromatin
morphology but less 15A3 immunoreactivity. Arrows point to the same neuron. Scale bar, 25 mm. (B) Motor neurons with strong 15A3
immunoreactivity had only minor mitochondrial vacuolization as examined by electron microscopy. Scale bar, 0.5 mm. (C) Motor neurons with strong
15A3 immunoreactivity did not have ubiquitinated protein aggregation.
doi:10.1371/journal.pone.0002849.g003
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PCR products were quite consistent with the signal intensities of
the oxidized mRNA species on the arrays.
We then used the computer program Onto-Express (http://
vortex.cs.wayne.edu/projects.htm#Onto-Express) to analyze the
identified oxidized mRNA species and grouped them according to
cellular component or molecular function [23]. The analysis based
on the cellular component showed that mRNA species encoded for
proteins that localized to mitochondria, ribosome and cytosol were
more susceptible to oxidation. The analysis based on the
molecular function showed that mRNA species encoded for
proteins that are involved in mitochondrial electron transport,
protein biosynthesis, myelination, protein folding and degradation,
cytoskeleton, tricarboxylic acid cycle and glycolysis, were more
susceptible to oxidation.
The signal intensities of the oxidized mRNA species on the
chips ranged from ,200 to ,12,000. There were 60 mRNA
species whose signal intensity was above 5,000, 298 mRNA species
whose signal intensity was between 2,000 and 5,000, 648 mRNA
species whose signal intensity was between 1,000 and 2,000, and
2,403 mRNA species whose signal intensity was below 1,000. We
considered those mRNA species, whose signal intensity was above
2,000, were highly oxidized. Table 1 shows the list of these mRNA
species grouped by their function (uncharacterized genes are not
listed). Importantly, some of these oxidized mRNAs appear to be
related to the pathogenesis of ALS. Several highly oxidized mRNA
species correspond to genes linked to familial ALS or ALS-like
human motor neuron disease, including SOD1, dynactin 1, and
vesicle-associated membrane protein 1.
These array results indicated that some mRNA species were
more susceptible to oxidative damage, which is consistent with our
previous observations in Alzheimer’s brains [12] and cultured
primary neurons under oxidative stress [13]. Thus, RNA oxidation
is not random, but highly selective. The highly abundant mRNA
species, b-actin and MAP2 have only very low level of mRNA
oxidation, indicating selective mRNA oxidation was not due to the
abundance of mRNA species. We also examined whether selective
mRNA oxidation was due to the up-regulation of mRNA
expression. Quantitative RT-PCR analysis revealed that those
highly oxidized mRNA species, such as ribosome protein S6,
cytochrome c oxidase Va, cytochrome c and MBP mRNAs, were
not up-regulated in SOD1
G93A spinal cords compared to non-
transgenic spinal cords (Fig. 4B). However, the up-regulation could
exist within specific cell types, e.g. motor neurons.
The above described 15A3 immunofluorescent staining (Fig 2)
indicated that at pre-symptomatic stage, increased RNA oxidation
primarily occurred in motor neurons and oligodendrocytes, not in
astrocytes and microglia. The array results showed that glial cell
specific mRNA species such as excitatory amino acid transporter 2
(EAAT2) and glial fibrillary acid protein (GFAP) mRNAs, which
are very abundant in the glial cells, were not present in the
oxidized mRNA pool. This indicates the specificity of the
identified oxidized mRNA species.
Some proteins corresponding to oxidized mRNA species
are decreased
Our previous studies demonstrated that oxidative modification
of mRNA causes reduced protein expression [11,12]. We
examined protein expression levels for the oxidized mRNA
species. Since the oxidized mRNAs primarily occur in motor
neurons, which are small portion of total spinal cord cell
population, immunoblot analysis was not sensitive enough to
detect the change, so immunofluorescent staining was performed.
The results showed that some proteins, whose mRNAs were highly
oxidized, were significantly decreased in the motor neurons of 60
day-old SOD1
G93A lumber spinal cords, such as cytochrome c
oxidase VIb (Fig. 5A, Cox VIb) and NADH-ubiquinol oxidoreduc-
tase subunit 39 kDa (Fig. 5B, NADH oxi). On the other hand, the
neuronal glutamate transporter EAAT3, whose mRNA was not
oxidized, was not decreased. Further, the white matter oligoden-
drocytes also showed significant mRNA oxidation in SOD1
G93A
mice (Fig. 2). MBP, whose mRNA was oxidized, was decreased as
determined by immunoblotting (Fig. 5C). These results suggested
that some proteins corresponding to oxidized mRNA species may
be decreased.
Vitamin E reduces mRNA oxidation in SOD1
G93A mice
We investigated whether mRNA oxidation contributes to motor
neuron degeneration. We first tested if vitamin E would reduce
mRNA oxidation. SOD1
G93A mice were orally fed with vitamin E
(200 IU/day per mouse, 5 days/week) at the age of 30-days (n=3
Figure 4. Some mRNA species are more susceptible to
oxidative damage in SOD1
G93A mice. (A) Semi-quantitative RT-
PCR analysis confirmed that the identified mRNA species by DNA
microarray were present in the oxidized mRNA pool. MBP, cytochrome
c, cytochrome c oxidase Va and ribosome protein S6 mRNAs, which had
strong signal intensities on the arrays, were present in the oxidized
mRNA pool. MAP2 and PCM1 mRNAs, which had very weak signal
intensities on the arrays, were hardly detected in the oxidized mRNA
pool. These oxidized mRNA species are significantly decreased in
vitamin E treated SOD1
G93A mice (G93A+vitE). (B) Semi-quantitative RT-
PCR analysis showed that the oxidized mRNA species are not
upregulated in the whole spinal cord of SOD1
G93A mice compared to
their non-transgenic littermates. SOD1 mRNA, which includes endog-
enous mouse SOD1 and transgenic human SOD1, was used as a control.
n=3.
doi:10.1371/journal.pone.0002849.g004
mRNA Oxidation in ALS
PLoS ONE | www.plosone.org 6 August 2008 | Volume 3 | Issue 8 | e2849Table 1. List of highly oxidized mRNA species in the spinal cord of 60 day-old SOD1
G93A mice.
Gene accession Gene title Intensity index* SD
protein biosynthesis
AK013880 asparaginyl-tRNA synthetase 2.2 6 0.8
BQ176989 eukaryote translation initiation factor 5 1.6 6 0.6
BC024899 eukaryote translation initiation factor 5a 1.6 6 0.8
BI693609 eukaryotic translation elongation factor 1 2.3 6 0.7
BC018223 eukaryotic translation elongation factor 1 alpha 1 1.5 6 1.0
NM_017404 mitochondrial ribosomal protein L39 3.9 6 3.9
NM_052835 ribosomal protein L10 1.5 6 0.5
AI506565 ribosomal protein L13 2.4 6 0.6
AI324936 ribosomal protein L13a 5.8 6 0.3
NM_001002239 ribosomal protein L17 3.5 6 1.0
AK008457 ribosomal protein L21 1.5 6 0.7
AV124394 ribosomal protein L23 6.9 6 0.7
BC002110 ribosomal protein L24 2.0 6 0.6
NM_013762 ribosomal protein L3 3.4 6 0.8
NM_009083 ribosomal protein L30 2.6 6 0.6
AV109882 ribosomal protein L31 5.8 6 1.1
BM114165 ribosomal protein L5 3.0 6 1.1
NM_011292 ribosomal protein L9 1.5 6 0.5
AI413680 ribosomal protein S12 2.4 6 0.9
BB724547 ribosomal protein S17 2.6 6 0.5
AV046829 ribosomal protein S20 3.2 6 1.1
NM_024277 ribosomal protein S27a 3.8 6 2.2
BC010987 ribosomal protein S28 4.6 6 0.7
AV037157 ribosomal protein S29 4.8 6 0.6
AW108231 ribosomal protein S3 2.6 6 0.6
NM_009096 ribosomal protein S6 4.7 6 0.7
NM_011300 ribosomal protein S7 2.4 6 0.4
NM_019883 ubiquitin A-52 residue ribosomal protein fusion product 1 4.6 6 0.6
Cytoskeleton
NM_013798 actin-like (Actl) 3.0 6 1.3
BB758476 actin-related protein 3 homolog 1.5 6 0.6
AV148266 cofilin 1, non-muscle 5.8 6 1.5
NM_011722 dynactin 6 2.2 6 0.8
NM_019682.1 dynein, cytoplasmic, light peptide 2.2 6 0.8
AV224521 gelsolin 4.1 6 0.5
AW494458 homolog to myosin regulatory light chain 1.8 6 0.8
NM_207682 kinesin heavy chain member 1B 1.7 6 0.5
AK161742 kinesin light chain 1 4.3 6 1.2
NM_019410 profilin 2 6.0 6 1.3
AV148480 thymosin, beta 10 2.2 6 0.8
NM_021278 thymosin, beta 4 2.5 6 1.1
BB559082 tubulin cofactor a 2.1 6 0.5
NM_010910 neurofilament, light polypeptide 5.1 6 1.3
NM_008691 neurofilament, medium polypeptide 3.4 6 1.6
NM_010904 neurofilament, heavy polypeptide 1.9 6 0.4
ATP biosynthesis
AV105788 ATPase, H+ transporting, lysosomal 34 kD, V1 subunit D 2.6 6 0.8
AV172216 ATPase, H+ transporting, lysosomal 16 kD, V0 subunit C 7.5 6 2.1
mRNA Oxidation in ALS
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BI154058 ATPase, H+ transporting, lysosomal 13 kD, V1 subunit G 3.5 6 1.0
sodium:potassium-exchanging ATPase activity
BG261955 ATPase, Na+/K+ transporting, beta 2 polypeptide 1.4 6 0.6
AV152334 ATPase, Na+K+ transporting, beta 1 polypeptide 6.2 6 0.6
Genes implicated in ALS and neurodegeneration
BC002066 Superoxide dismutase 1, soluble 2.2 6 1.0
NM_007835 dynactin 1 1.5 6 0.6
NM_009496 vesicle-associated membrane protein 1 1.5 6 0.7
AI848048 amyloid beta (A4) precursor-like protein 1 3.9 6 1.3
NM_030598 Down syndrome critical region gene 1-like 1 2.9 6 0.7
NM_011170 prion protein 3.6 6 1.0
Electron transport chain
Complex I
NM_026610 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 4 1.5 6 0.4
NM_023172 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9 2.7 6 1.3
NM_019443 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1 4.2 6 0.6
NM_028177 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1 1.8 6 0.6
NM_026614 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5 2.7 6 0.5
NM_025358.1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9 0.7 6 0.2
NM_028388 NADH dehydrogenase (ubiquinone) flavoprotein 2 3.2 6 1.8
Complex II
NM_023281 succinate dehydrogenase complex, subunit A, flavoprotein 1.5 6 0.6
Complex III
NM_025407 ubiquinol-cytochrome c reductase core protein 1 0.8 6 0.6
NM_025899 ubiquinol cytochrome c reductase core protein 2 2.0 6 0.5
NM_026219 ubiquinol-cytochrome c reductase binding protein 8.0 6 1.3
Complex IV
NM_009941 cytochrome c oxidase subunit IV isoform 1 1.6 6 0.3
NM_007747 cytochrome c oxidase, subunit Va 4.6 6 0.6
NM_009942 cytochrome c oxidase, subunit Vb 3.0 6 0.8
NM_025628 cytochrome c oxidase, subunit VIb polypeptide 1 5.0 6 0.5
NM_053071 cytochrome c oxidase, subunit VIc 4.3 6 1.0
NM_025567 cytochrome c-1 2.3 6 0.6
NM_007748 cytochrome c oxidase, subunit VI a, polypeptide1 5.6 6 0.8
NM_009945 cytochrome c oxidase subunit VIIa 2 5.2 6 1.0
ATP Synthase (Complex V)
NM_007505 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1 1.1 6 0.7
NM_009725 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b, isoform 1 3.0 6 1.0
NM_175015 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 3 3.9 6 1.2
NM_027862 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d 4.5 6 0.7
NM_007507 ATP synthase, H+ transporting, mitochondrial F1F0 complex, subunit e 1.4 6 0.1
NM_020582 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit f, isoform 2 1.6 6 1.4
NM_007512 ATPase inhibitory factor 1 1.5 6 0.2
Adenine Nucleotide Translocator
NM_007450 solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 4 5.7 6 1.0
NM_007451 solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 5 1.2 6 0.5
oxidoreductase activity
AV261043 similar to superoxide dismutase 3.2 6 1.1
Table 1. cont.
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BG060909 stearoyl-Coenzyme A desaturase 2 6.0 6 1.3
AK009462 aldo-keto reductase family 1, member A4 4.4 6 1.5
AV018774 L-3-hydroxyacyl-Coenzyme A dehydrogenase, short chain 3.7 6 1.6
NM_010239 ferritin heavy chain 7.0 6 0.8
NM_008133 glutamate dehydrogenase 1.3 6 0.7
BB166616 peroxiredoxin 1 3.9 6 0.4
AV300942 thioredoxin-like 2.0 6 0.9
TCA cycle
AV219418 lactate dehydrogenase 2, B chain 3.4 6 0.8
AV011848 malate dehydrogenase 1, NAD (soluble) 6.0 6 1.0
AV016940 malate dehydrogenase, mitochondrial 3.3 6 0.1
Glycolysis
AW558862 hexokinase 1 3.3 6 1.0
BC008184 aldolase 3 4.4 6 0.4
NM_007438 aldolase 1 1.9 6 0.6
BI407347 phosphoglycerate mutase 1 1.6 6 0.5
NM_013509 enolase 2, gamma neuronal 1.2 6 0.8
protein folding
NM_022310 Heat shock 70KD protein 5 1.4 6 1.0
NM_008907 peptidylprolyl isomerase A 2.9 6 0.9
BM941165 cytochrome c oxidase, subunit XVII assembly protein 1.7 6 0.3
BM210281 chaperonin subunit 6a (zeta) 1.2 6 0.8
C77287 heat shock protein 90 kDa alpha, class A member 1 4.0 6 1.3
BC006722 heat shock protein 8 1.8 6 1.3
AV038603 FK506 binding protein 1a 2.2 6 0.5
NM_009836.1 chaperonin subunit 3 (gamma) 2.1 6 0.8
NM_009964 crystallin, alpha B 2.1 6 0.6
proteasome
AV263662 proteasome (prosome, macropain) 26S subunit, ATPase 2 3.4 6 1.2
AV212146 proteasome (prosome, macropain) subunit, beta type 4 2.4 6 0.4
NM_011184 proteasome (prosome, macropain) subunit, alphatype 3 2.2 6 1.3
ubiquitin cycle
NM_019912 ubiquitin-conjugating enzyme E2D 2 2.9 6 1.0
BB315985 F-box and WD-40 domain protein 11 3.0 6 0.9
NM_019712 ring-box 1 3.1 6 1.4
AU080586 microtubule-associated protein 1 light chain 3 beta 5.8 6 4.2
lysosome
NM_010684 lysosomal membrane glycoprotein 1 2.7 6 0.7
BB560429 lysosomal-associated protein transmembrane 4B 3.8 6 0.8
calcium ion binding
NM_012061 Ca++dependent activator protein for secretion 2.1 6 0.9
BF608828 tumor protein, translationally-controlled 1 (Tpt1) 4.1 6 1.2
NM_010097 Sparc-like1 2.6 6 1.3
NM_012038 visinin-like 1 3.4 6 1.1
NM_016760 clathrin, light polypeptide 2.3 6 0.3
BG067649 epidermal growth factor receptor pathway substrate 15 2.0 6 1.1
NM_009722 ATPase, Ca++ transporting, cardiac muscle, slowtwitch 2 3.3 6 1.0
BC021347 calmodulin 2 (phosphorylase kinase, delta) 6.0 6 1.1
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AV015462 calmodulin 1 2.2 6 0.6
AV103412 transketolase 3.2 6 0.7
zinc ion binding
BB390675 matrin 3 4.4 6 1.0
BB833716 tetratricopeptide repeat domain 3.6 6 0.8
BC010197 Carboxypeptidase E 5.0 6 1.8
BB246182 The ring finger protein 157 3.0 6 0.9
NM_019712 ring-box 1 (Rbx1) 3.1 6 1.4
AA796766 metallothionein 2 2.1 6 0.8
NM_013602 metallothionein 1 2.6 6 0.8
protein serine/threonine kinase activity
BB453775 mitogen activated protein kinase 10 3.0 6 1.4
AW541674 mitogen activated protein kinase kinase 7 2.4 6 1.4
BF456404 p21 (CDKN1A)-activated kinase 1 3.0 6 0.8
BB234940 discoidin domain receptor family, member 1 3.6 6 1.9
Myelination
AV328388 myelin basic protein 11.7 6 0.2
BB768495 proteolipid protein 6.7 6 0.8
NM_008614 myelin-associated oligodendrocytic basic protein 3.5 6 1.0
NM_008885 peripheral myelin protein 3.8 6 0.7
glutamine biosynthesis
AI391218 glutamine synthetase 1.9 6 0.9
cell adhesion
NM_007614 catenin (cadherin associated protein), beta 1 3.0 6 1.1
BB066232 catenin (cadherin associated protein), alpha 1 2.3 6 0.7
protein modification
AW551908 ubiquitin C 3.6 6 1.6
NM_011664 ubiquitin B 7.6 6 0.9
NM_019883 ubiquitin A-52 residue ribosomal protein fusion product 1 4.6 6 0.6
vesicle-mediated transport
AF326545 syntaxin binding protein 1 1.8 6 0.4
neurotransmitter secretion
BC018249 synaptosomal-associated protein 25 kDa 2.1 6 1.3
nucleosome assembly
BB252350 H3 histone, family 3A 5.0 6 1.6
BC017540 TSPY-like 4 2.7 6 1.2
AV003424 H2A histone family, member Z 2.0 6 0.5
cell death
BB433678 clusterin 4.0 6 1.9
receptor mediated endocytosis
BB041005 sorting nexin 17 1.9 6 0.6
gap junction
BB039269 gap junction membrane channel protein alpha 1 3.4 6 0.5
Golgi stack
BE691746 serine incorporator 3 1.8 6 0.5
AB006361 prostaglandin D2 synthase (brain) 3.6 6 1.1
BC026372 Nedd4 family interacting protein 1 4.8 6 1.7
protein transport
Table 1. cont.
mRNA Oxidation in ALS
PLoS ONE | www.plosone.org 10 August 2008 | Volume 3 | Issue 8 | e2849Gene accession Gene title Intensity index* SD
NM_012061 Ca2+ dependent activator protein for secretion 2.1 6 0.9
AF326545 syntaxin binding protein 1 1.8 6 0.4
NM_009005 RAB7, member RAS oncogene family 1.9 6 0.9
AV339290 RAB14, member RAS oncogene family 2.2 6 0.8
BB396668 RAB6B, member RAS oncogene family 2.1 6 0.5
NM_019718 ADP-ribosylation-like 3 1.8 6 0.4
BF660710 guanosine diphosphate (GDP) dissociation inhibitor 3 2.3 6 0.8
nuclear mRNA splicing, via spliceosome
BC003745 DEADH (Asp-Glu-Ala-AspHis) box polypeptide 15 1.9 6 0.7
positive regulation of transcription
BB114677 DEAD (aspartate-glutamate-alanine-aspartate) box polypeptide 5 2.0 6 0.7
NM_007614 catenin beta 3.0 6 1.1
protein targeting
AV209126 signal recognition particle 14 kDa (homologous Alu RNA binding protein) 3.9 6 0.8
BB100384 tyrosine 3-monooxygenasetryptophan 5-monooxygenase activation protein, zeta 2.1 6 0.6
AV124281 tyrosine 3-monooxygenasetryptophan 5-monooxygenase activation protein, theta 4.3 6 1.2
NM_018871 3-monooxgenasetryptophan 5-monooxgenase activation protein, gamma polypeptide 2.9 6 0.8
BB106523 tyrosine 3-monooxygenasetryptophan 5-monooxygenase activation protein, epsilon 1.9 6 0.9
AV021552 tyrosine 3-monooxygenasetryptophan 5-monooxygenase activation protein, beta 5.4 6 0.3
Transcription
BB357514 TSC22 domain family, member 1 5.1 6 0.3
AF201285 TSC22-related inducible leucine zipper 1b 2.4 6 0.4
BB462744 retinoblastoma binding protein 4 3.3 6 1.5
AV122231 MORF-related gene X 3.7 6 1.2
AJ414734 53BP1 protein 2.8 6 1.3
regulation of progression through cell cycle
BC003856 Protein phosphatase 2, catalytic subunit, a isoform 1.8 6 0.6
AW907805 RAN, member RAS oncogene family 2.4 6 0.5
BB531646 Protein phosphatase 2, regulatory subunit, a isoform 6.4 6 3.8
Miscellaneous
NM_133354 SMT3 (supressor of mif two, 3) homolog 2 4.4 6 0.7
NM_007694 chromogranin B 1.5 6 0.7
BC002008 fatty acid binding protein 5, epidermal 5.5 6 1.1
NM_030692 SAC1 (supressor of actin mutations 1) 1.7 6 0.6
NM_021881 quaking protein 2.4 6 1.1
NM_008907 peptidylprolyl isomerase A 2.9 6 0.9
NM_053076 reticulon 3 4.9 6 1.3
AV028400 poly(A) binding protein, nuclear 1 2.8 6 1.0
AK016567 glycoprotein m6b 2.0 6 1.0
BB381966 integrator complex subunit 6 4.3 6 1.0
NM_008248 histidine triad nucleotide binding protein 1 6.3 6 0.9
BB005298 prolyl endopeptidase 3.1 6 1.5
AV006122 N-myc downstream regulated gene 4 6.7 6 0.8
NM_024166 coiled-coil-helix-coiled-coil-helix domain containing 2 8.9 6 1.1
NM_145942 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 6.1 6 0.4
AW742814 methionine aminopeptidase 2 1.7 6 0.5
BB274009 protein kinase, cAMP dependent regulatory, type I beta 3.3 6 1.2
AV148646 acetyl-Coenzyme A acetyltransferase 2 3.0 6 1.5
Table 1. cont.
mRNA Oxidation in ALS
PLoS ONE | www.plosone.org 11 August 2008 | Volume 3 | Issue 8 | e2849per group). The dosage of vitamin E was chosen based on high
dose vitamin E therapy in ALS patients [24]. After 30 days of
treatment (at age of 60-day), lumbar spinal cords were harvested
for analysis. Immunofluorescent staining (Fig. 6A) and immuno-
precipitation analysis (Fig 4A, compared G93A with G93A+vitE in
oxidized mRNA pool) revealed that mRNA oxidation level was
significantly decreased in the treated mice. The protein expression
levels for cytochrome c oxidase VIb, NADH-ubiquinol oxidore-
ductase subunit 39 kDa and myelin basic protein were partially
restored in the treated mice when compared to the non-treated
mice (data not shown). These results indicated that vitamin E
treatment can reduce mRNA oxidation in SOD1
G93A mice.
Reduced mRNA oxidation by vitamin E delays disease
onset, and improves motor performance, but does not
change survival
mRNA oxidative damage occurs at an early age of mice (Fig. 2),
but significant protein, lipid and DNA oxidative damage does not
occur until active disease progression stage [25–27]. Thus, any
protective effects by vitamin E in the early symptomatic stage may
be primarily due to reduced mRNA oxidation. We next
investigated if the reduction of mRNA oxidation by vitamin E
would delay the progression of ALS. The SOD1
G93A mice were
orally fed with vitamin E starting at the age of 30-days until they
reached the end stage of disease. Motor performance was
monitored by measuring grip strength. We found there was a
23% decline in grip strength in the non-treated mice (n=17) but
only an 8% decline in the treated mice at 90 days (n=17); there
was a 60% decline in the non-treated mice and a 40% decline in
the treated mice at 110 days (Fig. 6B). The cumulative probability
of onset, as defined by the grip strength deficit, was significantly
delayed (by ,15 days, p,0.01) in the treated mice (10666.1 days),
compared to the non-treated mice (9164.3 days) (Fig. 6C).
However, the mean life span was not significantly different
between the treated mice (12367.6 days, n=12) and the non-
treated mice (12267.3 days, n=13) (Fig. 6D). The disease
duration, defined as the period from the time of 50% decline in
grip strength to the time of death, was significantly shortened in
the treated mice (1064.8 days), compared to the non-treated mice
(1766.6 days, p,0.01) (Fig. 6E). These results indicated that
decreased mRNA oxidation by vitamin E can delay disease onset,
which is consistent with the previous study by Gurney et al. [28].
Reduced mRNA oxidation by vitamin E delays the
progressive loss of motor neurons, ubiquitin
aggregation, and gliosis, and significantly reduces
mitochondria vacuolization in motor neurons
One striking observation in the above onset study (Fig. 6) was
that at the age of 100 days, the non-treated mice exhibited grip
strength deficit and were sick while the treated mice still had
normal motor performance and remained active. However,
between 110 and 120 days of age, the treated mice developed
onset rapidly and died within a similar age range as the non-
treated mice. We therefore decided to examine the pathological
changes at 100 days and 120 days of age. To examine the numbers
and morphology of the motor neurons, we performed cresol violet
staining on the lumbar spinal cord sections from non-treated and
treated mice (n=3 per group). The results showed that at 100 days
of age, numerous of motor neurons were lost in the non-treated
mice, and the remaining motor neurons were atrophic. In
contrast, there was less motor neuron loss in sections from the
treated mice, and the motor neurons were healthier in
Gene accession Gene title Intensity index* SD
BI438046 ornithine decarboxylase antizyme 4.3 6 0.7
AV172168 calponin 3, acidic 2.2 6 0.6
AV348702 inositol (myo)-1(or 4)-monophosphatase 1 1.9 6 0.3
BB168483 chloride channel, nucleotide-sensitive, 1A 2.3 6 0.4
AA038464 Nur77 downstream gene 2 1.8 6 0.3
BB251922 cyclic nucleotide phosphodiesterase 1 6.4 6 0.3
AV207950 phosphatidylethanolamine binding protein 1 5.0 6 1.1
BB043450 protein tyrosine phosphatase 4a1 4.9 6 1.7
AV296285 beclin 1 (coiled-coil, myosin-like BCL2-interacting protein) 2.9 6 0.3
NM_010490 CCR4 carbon catabolite repression 4-like 2.4 6 1.1
NM_007756 complexin 1 6.2 6 2.3
BC001991 selenoprotein P, plasma, 1 2.9 6 0.6
BG967663 creatine kinase, brain 1.9 6 0.5
AI987693 gag protein 4.5 6 1.6
AV124445 necdin 4.0 6 1.1
AV019984 diazepam binding inhibitor 2.7 6 1.1
AV309418 N-myc downstream regulated 1 2.8 6 1.0
AV310432 retinoblastoma binding protein 7 2.5 6 0.8
BB722680 heterogeneous nuclear ribonucleoprotein K 4.9 6 0.9
BM200248 paternally expressed 3 3.0 6 1.2
*intensity index, the average of signal intensities on three arrays divided by 1,000; SD, standard deviations among three arrays.
doi:10.1371/journal.pone.0002849.t001
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However, at 120 days of age, there was no obvious difference
between treated and non-treated mice samples, in that the
majority of motor neurons had degenerated (not shown). We also
performed toluidine blue staining (Fig. 7B), and the results were
consistent with the cresol violet staining results. Importantly, there
was significant vacuolization in the non-treated mice and only a
slight vacuolization in the treated mice at 100 days of age. These
results clearly indicated that vitamin E can reduce mRNA
oxidation, restore protein expression level and partially protect
motor neurons up to 100 days of age. Notably, significant protein
oxidation [25], lipid peroxidation [26] and DNA oxidation [27]
occurs at active disease progression stage; thus, the observed
protective effects by vitamin E are primarily due to reduction of
RNA oxidation.
We examined the effects of vitamin E on the occurrence of the
following events associated with SOD1
G93A mice: gliosis, ubiquitin
aggregation, and mitochondria vacuolization. At 100 days of age,
both GFAP immunostaining, a marker for reactive gliosis, and
ubiquitin immunostaining, a marker for protein aggregation, were
significantly reduced in the treated mice, compared to the non-
treated mice (Fig. 7B). However, at 120 days of age, no obvious
difference was observed (not shown), suggesting that these are
probably secondary events to motor neuron degeneration.
Figure 5. Some proteins corresponding to oxidized mRNA species are decreased. (A&B ) immunofluorescent staining of lumbar spinal
cord sections prepared from indicated mice (n=3) showed that downregulation of protein levels in SOD1
G93A mice was found in cytochrome c
oxidase VIb (Cox VIb) and NADH-ubiquinol oxidoreductase subunit 39 kDa (NADH oxi), whose mRNAs were highly oxidized but not EAAT3 protein,
whose mRNA was not oxidized. Statistic analysis of immunoreactivity within motor neurons (n=20) is shown. *P,0.0001 (C) Immunoblot analysis
showed that MBP, whose mRNA was oxidized, was decreased. Densitometry analysis (standardized by actin intensity) of immunoblot is shown (n=3).
#P,0.01.
doi:10.1371/journal.pone.0002849.g005
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chondrial morphology of motor neurons. As shown in Figure 7C,
severely swollen mitochondria with disorganized and dilated
cristae were observed in the motor neurons of 75 day-old
SOD1
G93A mice. Significantly, the treated mice exhibited mostly
normal mitochondrial morphology at 75 days, and even at 102
days, the mitochondria only slightly vacuolated, and the cristae
were clear (not severely damaged). These results suggest that
mitochondria vacuolization may be highly associated with RNA
oxidation. One important result supporting this possibility is that,
as described above, many mRNAs encoding proteins involved in
mitochondrial functions were highly oxidized (Table 1).
Discussion
In the present study, we found that mRNA oxidation is a
common feature in ALS patients and mutant SOD1 transgenic
mice and also an early event preceding motor neuron degener-
ation. This study suggests that mRNA oxidation may contribute to
motor neuron deterioration in ALS.
Figure 6. Vitamin E reduces RNA oxidation and delays the disease onset, but not the survival. (A) immunofluorescent staining of lumbar
spinal cords sections prepared from indicated mice showed that RNA oxidation is significantly decreased in vitamin E treated mice (n=3 per group).
Statistical analysis of immunoreactivity within motor neurons (n=20) is shown. *P,0.01 (B & C) The decline in motor performance by measuring grip
strength was significantly delayed (,14 days, *P,0.005) in the vitamin E treated mice. There was no significant difference in the life span between
the vitamin E treated and non-treated mice (D). The disease duration is significantly shortened (*P,0.01) (E). n=17 each group.
doi:10.1371/journal.pone.0002849.g006
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non-oxidized mRNAs and subsequently quantified and identified
oxidized mRNAs. The specificity of 15A3 antibody is very
important. This was validated by including the no antibody
control and the 8-OHG-blocked antibody control in each
experiment. In addition, we analyzed the 15A3-precipitated
mRNAs by HPLC-ECD (high-performance liquid chromatogra-
phy coupled with electrochemical detection) and confirmed that
the mRNAs recognized by 15A3 contained high levels of 8-OHG.
This indicates that the isolated/detected mRNAs were oxidized
mRNAs.
In the ALS postmortem tissues study (Fig. 1), we found that
mRNAs are oxidatively damaged to a variable extent in ALS
patients. Interpretation of human postmortem tissue pathological
changes is difficult, since postmortem tissue represents the very
end stage of the neurological disease and reflects the cells that
remain but not necessarily those that are at risk. The mutant
SOD1 mice studies provide the valuable information of the role of
Figure 7. Effect of vitamin E on the course of disease in SOD1G93A mice. (A) Cresyl violet-stained and toluidine blue-stained sections
through the ventral horn of lumbar spinal cord showed partial preservation of neurons in vitamin E treated mice compared with non-treated mice at
age of 100 days. The number of motor neurons in the lumbar spinal cord was counted (n=3 per group, *P,0.01). Vitamin E delays the progressive
loss of motor neurons. (B) Immunofluorescent staining of lumbar spinal cord sections showed that gliosis (GFAP staining) and ubiquitin aggregation
(ubiquitin staining) were significantly reduced in vitamin E treated mice (100 day-old). The ventral horn area is shown. Scale bar, 10 mm. (C) Electron
microscopy shows that vitamin E significantly reduces mitochondria vacuolization in motor neurons. Scale bar, 0.5 mm.
doi:10.1371/journal.pone.0002849.g007
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G93A mice
study, we speculate that significantly increased mRNA oxidation
may occur in the motor neurons and oligodendrocytes of ALS-
affected areas at the prodromal stage. This may contribute to
neuronal deterioration and in combination with other toxicities
eventually leading to motor neuron degeneration.
Previous studies in SOD1
G93A mice showed that significant
increases in lipid, protein and DNA oxidation occurs during
symptomatic stage [25–27]. We found that mRNA oxidation
occurs as early as 45 days, progressively increases with age, until it
peaks at 60–70 days of age, and then diminishes when the motor
neurons begin to degenerate (Fig. 2). Those motor neurons
showing RNA oxidation appear to be still healthy as judged by the
nuclear and chromatin morphology and mitochondrial morphol-
ogy (Fig. 3). These results indicate that mRNA oxidation is an
early event.
RNA oxidation primarily occurs in motor neurons and
oligodendrocytes at pre-symptomatic stage (Fig. 2). This indicates
that both cell types are more vulnerable to RNA oxidation. Like
neurons, oligodendrocytes are highly vulnerable to injury by
oxidative stress [29]. Oligodendrocytes, compared to other cells,
have a high lipid content, high iron content, and low supplies of
cellular antioxidant [30].
Increased mRNA oxidation also occurs in the pre-symptomatic
stage of mice expressing other mutant SOD1 (Fig. 1E). Mutant
SOD1
G37R, like SOD1
G93A, retains full dismutase activity [31].
Both SOD1
G85R and SOD1
G127X lack dismutase activity and are
unstable [32,33]. Mutant SOD1
H46R/H48Q possesses little or no
SOD1 activity [34]. The protein levels of mutant SOD1 in these
mice are different: SOD1
G93A, SOD1
G37R, SOD1
G85R and
SOD1
G127X mice express 17-, 5-, 0.9- and 0.45-fold human
mutant SOD1 of mouse wild type SOD1, respectively [20]. This
suggests that increased RNA oxidation is a common feature in
these ALS mouse models and has nothing to do with SOD1
activity or mutant SOD1 expression level. What could be the
possible mechanism underlying ROS formation in these mutant
SOD1 mice? We would like to propose one possible mechanism.
Ferri et al. have demonstrated that one common property of
different FALS-mutant SOD1s with widely differing biophysical
properties is the association with mitochondria to a much greater
extent than wild-type SOD1 [35]. Mutant SOD1 proteins
associated with the mitochondria tend to form cross-linked
oligomers and impair mitochondrial function, which could lead
to increased ROS formation.
Identification of oxidized mRNA species by DNA microarray
revealed that some mRNA species are more susceptible to
oxidative damage, which was also observed in our previous
studies [11,12]. The phenomenon of selective RNA oxidation was
not related to the abundance of mRNA species or the up-
regulation of mRNA expression. No common motifs, sequences or
structures were found in oxidized mRNA species at this time.
Several possible mechanisms are currently under investigation.
A very striking finding in this study is that many identified
known oxidized mRNAs are related to ALS: (1) mRNAs
corresponding to genes linked to familial ALS or ALS-like human
motor neuron disease, including SOD1, dynactin 1, and vesicle-
associated membrane protein 1 (VAMP) mRNAs. A missense
mutation in the p150 subunit of the dynactin (DCTN1) gene has
been described in a human kindred with a slowly progressive,
autosomal dominant form of lower motor neuron disease [36,37].
A dominant missense mutation in the VAMP-B gene (ALS8) has
been linked to an atypical ALS that is accompanied by an unusual
tremor [38]. VAMP-B interacts with VAMP-A involving in
vesicular trafficking [39]. (2) mRNAs encoding neurofilament
subunits. The genes encoding three neurofilament subunits have
long been suspected as causative for ALS because of their link with
motor neuron pathology in mice and humans [40]. (3) mRNAs
encoding proteins involved in protein folding and degradation.
Reduction of proteasome 26S function and protein chaperone
activities have been found in SOD1
G93A transgenic mice [41,42].
Impaired function of protein folding and degradation pathway can
lead to protein aggregation, one of hallmarks of ALS. (4) mRNAs
encoding proteins involved in the mitochondrial electron transport
chain (ETC). Dysfunction of mitochondrial ETC has been
previously found in SOD1
G93A mice and ALS patients [43,44].
It is possible that mRNA oxidation is responsible for the observed
dysfunction and also the mitochondria vacuolization (Fig. 7C). (5)
mRNAs encoding proteins involved in glycolysis and tricarboxylic
acid (TCA) cycle. Depleted ATP levels and reduction of glucose
use have been reported in spinal cords of SOD1
G93A mice at pre-
symptomatic stage [45]. Abnormal glycolysis and TCA process
combined with mitochondrial electron transport chain dysfunction
could result in ATP synthesis impairment. (6) mRNAs encoding
metallothioneins. Metallothioneins, known to bind copper ions
and decrease oxidative toxicity, have been suggested to have
important roles in the pathophysiology of ALS [46–48]. (7)
mRNAs encoding proteins involved in protein transport. Defective
axonal transport has been found to cause late-onset progressive
degeneration in transgenic mice [49]. Dominant point mutations
in dynein causing motor neuron disorders have been found in both
ALS patients and mouse models [37]. (8) mRNAs encoding
proteins involved as structural constituents of myelin sheath,
including MBP, proteolipid protein (PLP) and myelin-associated
oligodendrocytic basic protein (MOBP). MBP was reported to be
related to axon degeneration [50]. MBP protein level is
significantly decreased in ALS spinal cords [51]. We show that
MBP protein is significantly decreased in the presymptomatic
stage of SOD1
G93A spinal cords (Fig. 5C). mRNA oxidation may
be responsible for loss of MBP protein. Myelin sheaths contribute
to the structure and stability of the axons [52]. Abnormally
expressed myelin proteins may affect axon stability and contribute
to axon degeneration.
We examined protein expression levels for the oxidized mRNA
species and found that some proteins corresponding to oxidized
mRNA species are decreased (Fig. 5). Our previous studies
demonstrated that oxidized bases in mRNAs can cause ribosome
stalling on the transcripts, leading to decreased protein expression
[13]. A recent study [14] demonstrates that oxidized mRNA
induces translation errors, producing short polypeptides because of
premature termination or translation error-induced degradation.
Does mRNA oxidation contribute to the pathogenesis of the
disease? We approached this question by treating SOD1
G93A mice
with vitamin E. As mentioned above, RNA oxidation occurs at an
early age of mice, but significant protein, lipid and DNA
oxidations do not occur until active disease progression stage
[25–27]; thus, the protective effects by vitamin E in the early
symptomatic stage may be primarily due to reduced mRNA
oxidation. Four observations strongly support that mRNA
oxidation does contribute to the disease. First, the protein
expression levels for the oxidized mRNA species are decreased
(Fig. 5). Second, the vitamin E treated mice still had normal motor
performance and were still active at the age of 100 days while the
non-treated mice were already sick (Fig. 6). The treated mice
developed onset rapidly between 110 and 120 days and died
within a similar age range as the non-treated mice. This is
probably because reduced mRNA oxidation by vitamin E partially
diminishes toxicity in motor neurons, but toxicities from other
non-neuronal cells are still present. Third, reduced mRNA
mRNA Oxidation in ALS
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vacuolization in motor neurons (Fig. 7C). Finally, many identified
known oxidized transcripts are related to ALS. RNA oxidation
may account for many neuropathological changes reported
previously.
Dietary supplement with vitamin E is widely used in the clinical
as an antioxidant for ALS patients. Although in previous studies
vitamin E did not prolong survival of ALS patients [24], Ascherio
et al. found that those individuals who took vitamin E supplements
for 10 years had less than 50% risk of death from ALS than that of
vitamin E nonusers [53]. These studies support our observations in
SOD1
G93A mice that RNA oxidation is an early event and
contributes to motor neuron degeneration. Thus, blocking RNA
oxidation at prodromal stage may prevent/slow the disease
progression; however, at the disease stage, the antioxidant
treatment may be already too late so there is no significant
beneficial effect.
Methods
ALS tissues
ALS brain and spinal cord tissues were obtained from the Johns
Hopkins ALS Brain Bank. Postmortem delays for autopsy were
7.360.8 hr. Pathological confirmation of ALS was made on all
specimens by standard histological evalution of spinal cord and
motor cortex, with use of hematoxylin and eosin to evaluate motor
neuron loss, and with myelin stains (Luxol-fast blue) to establish
corticospinal tract degeneration.
Animal model
All animal experiments were performed at Ohio State
University under national and institutional guidelines using
protocols approved by the the Animal Care & Use Committee
of Ohio State University. Human SOD1
G93A transgenic mice
(B6SJL-Tg [SOD1-G93A] 1Gur with high copy number of the
mutant human SOD1 gene) and human wild-type SOD1
transgenic mice (B6SJL-Tg [SOD1-G93A] 2Gur) were purchased
from Jackson Laboratory (Bar Harbor, ME). Adult same gender
mice were housed 5 per cage, under 12 h dark/light cycles.
Transgene was determined by PCR using genomic DNA extracted
from tail biopsies. From the time when transgenic mice showed
motor deficits, food and water were placed on the cage floor.
Transgenic animals were killed when they can not right themselves
within 30 sec.
Tissue collection and RNA isolation
After decapitation, spinal cords were removed and dissected
rapidly. The samples were placed in individual tubes and
homogenized in 1 ml of Trizol reagent (Invitrogen, Carlsbad,
CA). RNA isolation was performed according to the manufactur-
er’s protocol. After DNase I (Invitrogen) treatment, poly(A)
+ RNAs
were isolated using the Oligo-tex mRNA Purification Kit (Qiagen
Inc., Valencia, CA).
Immunohistochemistry
Mice were perfused transcardially with 4% paraformaldehyde
after being deeply anesthetized with tribromoethanol (Avertin;
200 ml/10 g intraperitoneally). The brains and spinal cords were
rapidly removed and cryoprotected with 20% sucrose for 24 h.
The sections were blocked in 8% normal goat serum (NGS;
Vector Laboratories, Burlingame, CA) and 0.1% Triton X-100 in
Tris-buffered saline (TBS) for 60 min and incubated in primary
antibody solution overnight at 4uC. After thorough washing with
TBS, the sections were then incubated with secondary antibody in
TBS containing 2% NGS for 60 min at 4uC followed by thorough
washing with TBS. The following primary antibodies were used in
this study: rabbit anti-ubiquitin pAb (1:50, Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA ), mouse anti-8-OHG mAb (1:250,
QED Bioscience, San Diego, CA), rabbit anti-EAAT3 pAb
(1:1000), mouse anti-NADH-ubiquinol oxidoreductase 39 kDa
Subunit, (1:2000, Molecular Probes, Carlsbad, CA), mouse anti-
cytochrome c oxidase VIb Subunit (1:750, Molecular Probes).
Images were obtained using a Zeiss Axioskop 2 upright
microscope and AxioVision software.
Tissue preparation and Electron microscopy
Mouse spinal cords were initially fixed by intracardiac perfusion
with a solution of 0.1% sodium phosphate (pH 7.6), 4%
paraformaldehyde, and 2.5% glutaraldehyde, and postfixed in
1% osmium tetroxide, and embedded in Eponate 12 (Ted Pella,
Redding, CA). One-micrometer sections were stained with
toluidine blue. Motor neurons were identified by their large size
(.20 mm) and distinct nuclear morphologies in the ventral horn of
the lumbar cord.
Cresyl violet staining and motor neuron counts
For motor neuron counting, the L5 lumbar spinal cords were
sectioned at 20 mm with a Microm cryostat at 225uC. Every fifth
section was stained with 0.1% (w/v) cresyl violet solution. Motor
neurons in the ventral horn were quantified by counting large
pyramidal neurons that stain with cresyl violet and possess a
prominent nucleolus. 14 sections of spinal cord were counted per
mouse, and the analysis was performed blindly. Three animals per
genotype were analyzed.
Immunoprecipitation
Poly(A)
+ RNAs (1.5 mg) were incubated with 1.5 mg of anti-8-
OHG antibody (15A3) at room temperature for 4 hr. For negative
controls, the primary antibody was omitted or pre-incubated with
24 ng/ml of 8-OHG (Cayman Chemical, Ann Arbor, MI).
Immobilized Protein L gel beads (20 ml) (Pierce, Rockford, IL)
were added and incubated at 4uC for an additional 15 hr. The
beads were washed three times with PBS and 0.04% (v/v) NP-40
(Roche Applied Sciences, Indianapolis, IN). Afterward, the
following items were added in the following order: 300 mlo f
PBS with 0.04% NP-40, 30 ml of 10% (w/v) SDS, and 300 mlo f
PCI (phenol:chloroform:isoamyl alcohol, 25:24:1). The mixture
was incubated at 37uC for 15 min (vortex every 5 min) and
separated to aqueous phase and organic phase by spinning at
14,000 rpm for 5 min. The aqueous layer was collected and mixed
with 40 ml of 3 M sodium acetate, pH 5.2, 2 ml of 5 mg/ml
glycogen, plus 1 ml of 95% (v/v) ethanol. The sample was frozen
at 280uC for 1 hr and centrifuged for 20 min. The pellet was
washed with 75% ethanol, air-dried and then resuspended in 14 ml
of DEPC-treated H2O.
cDNA synthesis and Southern blotting
Immunoprecipitated mRNAs were reversely transcribed using
avian myeloblastosis virus (AMV) reverse transcriptase kit (Roche
Applied Sciences). For 15 ml of reaction mixture, 7 mlo f
immunoprecipitate mRNAs and 1 ml (0.75 mg) of oligo-(dT) 24-
T7 primer were mixed and incubated at 70uC for 10 min. After
2 min on ice, the master mix contained 7 mlo f5 6 first-strand
buffer, 0.5 mM 29-deoxynucleoside 59-triphosphates [deoxy (d)-
ATP, dCTP and dGTP], 0.13 mM 29-deoxythymidine-59-triphos-
phate, 0.03 mM digoxigenin-11-29-deoxy-uridine-59-triphosphate
(Roche Applied Sciences), 2.5 U of RNase Inhibitor (Invitrogen),
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incubated at 42uC for 90 min. cDNAs were resolved in 1%
agarose gel and then transferred electrophoretically to a positively
charged nylon membrane (Roche Applied Sciences) using the
Trans-Blot SD semidry transfer system (Bio-Rad, Hercules, CA)
according to the directions of the manufacturer. Digoxogenin
labeled on cDNAs was detected with a Digoxogenin High Prime
DNA Labeling and Detection Starter Kit II (Roche Applied
Sciences).
Microarray hybridization
Preparation of cRNA was performed according to the Two-
cycle cRNA amplification protocol provided by Affymetrix (Santa
Clara, CA). The immunoprecipitated oxidized mRNA was
converted to cDNA using AMV reverse transcriptase and a
GeneChip T7-oligo(dT) primer 59-GGCCAGTGAATTGTAA-
TACGACTCACTATAGGGAGGCGG-(dT)24-39(Affymetrix).
For the first-cycle IVT amplification of cRNA, a MEGAscript T7
kit (Ambion Inc., Austin, TX) was used. The cRNA was purified
and cleanup by using RNeasy mini kit (Qiagen). Each cRNA
sample was synthesized from 2 independent biological samples.
Biotin-labeled cRNA was synthesized from second-cycle cDNA
using an IVT Labeling Kit (Affymetrix). The yield of the in vitro
transcription reaction was determined by product absorbance at
260 nm measured by NanoDrop ND-1000 (NanoDrop Technol-
ogies, Inc., Montchanin, DE). Size of cRNA probes was evaluated
by using RNA 6000 Nano LabChip Kit (Agilent, Palo Alto, CA,
USA). Experion Automated Electrophoresis System was used to
examine the quality of samples (Affymetrix). Fragmented cRNA
(15 mg) was used for hybridization to GeneChip Mouse Genome
430 2.0 arrays (Affymetrix).
RT-PCR
Immunoprecipitated mRNAs were reversely transcribed with
AMV reverse transcriptase (Roche) and Oligo-(dT)24 primer.
PCRs were performed in the presence of 3 mM MgCl2, 0.2 mM
dNTP, 0.25 mM primers and 2 U Taq DNA polymerase
(Invitrogen) in 16 PCR buffer, with gene–specific primers,
including Cu/Zn SOD1 F (59-atggcgacgaaggccgtgtgcgt) and R
(59-ctggcaaaatacaggtcattgaaacagaca), MAP2 F (59-ttggctcacttga-
caatgctcacc) and R (59-aatatgacacctgctcagagccca-39), MBP F (59-
agcatgccttctgtagaccttcca) and R (59-agtaggtgcttctgtccagccata), ri-
bosomal protein S6 F( 5 9-tgatgtccgccagtatgttgtcag) and R (59-
tggcttccttcattcttggc), Cox Va F (59-gacattgatgcctgggaattgcgt) and R
(59-ttacactttgtcaaggcccagctc), Cyc C F (59-tgttcactggcctctttcaggtca)
and R (59-ccagttatgtgtgtttctgagtggg), PCM F (59-aaagaacctgaaa-
cagtgggagcc) and R (59-ccaaatgtcacaatgaagggtggg). A series of
cycles (25, 30, 35 cycles) was performed (95uC for 30 s, specific
annealing temperature to each set of primers for 45 s, and 72uC
for 1 min). PCR products were visualized as single bands on 1%
agarose gels stained with ethidium bromide.
Immunoblotting
Immunoblotting was performed as described previously [54].
Briefly, protein extracts were generated from spinal cord, resolved
by SDS-PAGE and transferred onto PVDF membranes. The
following primary antibodies were used: rabbit anti-MBP pAb
(1:3000; Chemicon International, Inc, Temecula, CA), goat anti-
b-Actin (1:3000; Santa Cruz, CA). The immunoreactive bands
were detected using the SuperSignal West Pico Chemiluminescent
Substrate (Pierce Biotechnology, Rockford, IL) according to
manufacturer’s directions.
Vitamin E treatment
SOD1
G93A transgenic (n=32) mice were treated with vitamin
E, and their littermates SOD1
G93A (n=32) and wild type mice
(n=32) were used as controls. Mice were orally fed with vitamin E
(200IU/each for 5 day/week) from daily supplemental softgels
(Meijer Distribution, INC., Grand Rapids, MI), and started at age
of 30-days. The same gender littermates of wild type, G93A, and
vitamin E-treated G93A transgenic mice were used to compare
their onset, survival, and pathological changes, although no
significant variation of onset and survival were detected between
different genders.
Grip Strength
An objective assessment of neuromuscular performance was
obtained by measuring peak force generated using a Digital Grip
Strength Meter outfitted with a Hind Limb Pull Bar Assembly
(Columbus Instruments). Five repetitions were taken and the
average was determined for each mouse. The examiner was
unaware of the genotypes of the mice during measurement. Once
each litter of mice reached the age of 70 days, the grip strength
was measured twice a week, on the same day of each week and at
the same time of each scheduled day (within 2 h).
Statistical analysis
The quantitative data in this study were expressed as the
mean6SEM. Statistical analysis was performed using the unpaired
Student’s t-test.
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